Poller L, Samama M
University of Manchester, United Kingdom.
Clin Lab Med. 1994 Dec;14(4):813-23.
The safety and success of oral anticoagulant treatment are dependent on laboratory control by the prothrombin time test. Until recently, the therapeutic range in prothrombin ratios of 2.0 to 2.5 resulted in greatly different dosage regimes, because of the lack of standardization of the test, particularly its thromboplastin component. Low-dose warfarin was associated with responsive thromboplastin. In North America and many other countries, a high-dose regime from high international sensitivity index thromboplastin caused more bleeding.
口服抗凝治疗的安全性和成功率取决于通过凝血酶原时间试验进行的实验室监控。直到最近，凝血酶原比率在2.0至2.5的治疗范围导致了差异极大的剂量方案，因为该试验缺乏标准化，尤其是其凝血活酶成分。低剂量华法林与反应性凝血活酶有关。在北美和许多其他国家，高国际敏感指数凝血活酶导致的高剂量方案造成了更多出血。
